Martin LA - Search Results

1

mTOR inhibitors in advanced breast cancer: ready for prime time?

Martin LA, André F, Campone M, Bachelot T, Jerusalem G. Martin LA, et al. Cancer Treat Rev. 2013 Nov;39(7):742-52. doi: 10.1016/j.ctrv.2013.02.005. Epub 2013 Apr 1. Cancer Treat Rev. 2013. PMID: 23557794 Review.

2

Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, Dowsett M. Johnston SR, et al. Among authors: martin la. Clin Cancer Res. 2003 Jan;9(1 Pt 2):524S-32S. Clin Cancer Res. 2003. PMID: 12538510 Review.

3

Mechanisms of resistance to aromatase inhibitors.

Dowsett M, Martin LA, Smith I, Johnston S. Dowsett M, et al. Among authors: martin la. J Steroid Biochem Mol Biol. 2005 May;95(1-5):167-72. doi: 10.1016/j.jsbmb.2005.04.022. J Steroid Biochem Mol Biol. 2005. PMID: 15982868 Review.

4

Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.

Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M. Martin LA, et al. Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S75-84. doi: 10.1677/erc.1.01023. Endocr Relat Cancer. 2005. PMID: 16113101

5

Life following aromatase inhibitors--where now for endocrine sequencing?

Johnston SR, Martin LA, Dowsett M. Johnston SR, et al. Among authors: martin la. Breast Cancer Res Treat. 2005;93 Suppl 1:S19-25. doi: 10.1007/s10549-005-9038-2. Breast Cancer Res Treat. 2005. PMID: 16247596 Review.

6

Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer.

Johnston SR, Martin LA, Leary A, Head J, Dowsett M. Johnston SR, et al. Among authors: martin la. J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):180-6. doi: 10.1016/j.jsbmb.2007.05.019. Epub 2007 May 24. J Steroid Biochem Mol Biol. 2007. PMID: 17624764 Review.

7

The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.

Martin LA, Head JE, Pancholi S, Salter J, Quinn E, Detre S, Kaye S, Howes A, Dowsett M, Johnston SR. Martin LA, et al. Mol Cancer Ther. 2007 Sep;6(9):2458-67. doi: 10.1158/1535-7163.MCT-06-0452. Mol Cancer Ther. 2007. PMID: 17876043

8

Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?

Johnston SRD, Leary A, Martin LA, Smith IE, Dowsett M. Johnston SRD, et al. Among authors: martin la. Cancer. 2008 Feb 1;112(3 Suppl):710-717. doi: 10.1002/cncr.23190. Cancer. 2008. PMID: 18072235 Free article.

9

The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.

Banerjee S, Pancholi S, A'hern R, Ghazoui Z, Smith IE, Dowsett M, Martin LA. Banerjee S, et al. Among authors: martin la. Clin Cancer Res. 2008 May 1;14(9):2656-63. doi: 10.1158/1078-0432.CCR-07-1352. Clin Cancer Res. 2008. PMID: 18451229 Clinical Trial.

10

ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2.

Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S, Johnston S, Dowsett M, Martin LA. Pancholi S, et al. Among authors: martin la. Endocr Relat Cancer. 2008 Dec;15(4):985-1002. doi: 10.1677/ERC-07-0240. Epub 2008 Sep 29. Endocr Relat Cancer. 2008. PMID: 18824559

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

309 results

Search Page

Filters